Free Trial

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Bought by Healthcare of Ontario Pension Plan Trust Fund

Arrowhead Pharmaceuticals logo with Medical background

Healthcare of Ontario Pension Plan Trust Fund raised its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 63.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 95,000 shares of the biotechnology company's stock after buying an additional 37,000 shares during the period. Healthcare of Ontario Pension Plan Trust Fund owned about 0.08% of Arrowhead Pharmaceuticals worth $2,907,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in ARWR. FMR LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 58.2% in the 3rd quarter. FMR LLC now owns 4,308,903 shares of the biotechnology company's stock worth $115,780,000 after buying an additional 1,584,425 shares during the last quarter. Norges Bank bought a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter worth $40,451,000. Goldman Sachs Group Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 136.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,061,967 shares of the biotechnology company's stock worth $32,496,000 after buying an additional 613,067 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in shares of Arrowhead Pharmaceuticals by 100.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 1,130,000 shares of the biotechnology company's stock valued at $34,578,000 after purchasing an additional 565,000 shares in the last quarter. Finally, Capital International Investors boosted its stake in shares of Arrowhead Pharmaceuticals by 55.2% in the 4th quarter. Capital International Investors now owns 1,277,560 shares of the biotechnology company's stock valued at $39,093,000 after purchasing an additional 454,631 shares in the last quarter. Institutional investors own 62.61% of the company's stock.


Insider Activity at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Hongbo Lu purchased 1,000 shares of the stock in a transaction that occurred on Wednesday, March 20th. The stock was bought at an average cost of $27.50 per share, with a total value of $27,500.00. Following the transaction, the director now directly owns 33,680 shares in the company, valued at approximately $926,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Arrowhead Pharmaceuticals news, Director Victoria Vakiener sold 1,799 shares of Arrowhead Pharmaceuticals stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total value of $41,934.69. Following the completion of the transaction, the director now directly owns 30,205 shares of the company's stock, valued at $704,078.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Hongbo Lu bought 1,000 shares of the firm's stock in a transaction on Wednesday, March 20th. The stock was purchased at an average cost of $27.50 per share, with a total value of $27,500.00. Following the completion of the acquisition, the director now directly owns 33,680 shares of the company's stock, valued at approximately $926,200. The disclosure for this purchase can be found here. 4.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ARWR shares. Morgan Stanley cut their price objective on shares of Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an "equal weight" rating for the company in a research note on Monday, May 13th. The Goldman Sachs Group started coverage on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, June 5th. They issued a "neutral" rating and a $31.00 price objective for the company. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, June 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $90.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, June 11th. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $47.89.

View Our Latest Analysis on ARWR

Arrowhead Pharmaceuticals Stock Down 6.1 %

Shares of ARWR traded down $1.53 during trading hours on Tuesday, reaching $23.58. 838,888 shares of the company traded hands, compared to its average volume of 1,327,250. The company's fifty day moving average price is $24.19 and its two-hundred day moving average price is $28.31. The company has a market capitalization of $2.93 billion, a price-to-earnings ratio of -5.58 and a beta of 0.94. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $20.67 and a 12 month high of $39.83.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 140.72%. The company's revenue was down 100.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.45 EPS. On average, analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.05 EPS for the current year.

Arrowhead Pharmaceuticals Profile

(Free Report)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Featured Stories

Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Should you invest $1,000 in Arrowhead Pharmaceuticals right now?

Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.

While Arrowhead Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Roaring Kitty's GameStop Gamble: What Went Wrong?

Roaring Kitty's GameStop Gamble: What Went Wrong?

Keith Gill, aka Roaring Kitty, turned a modest investment into a massive payday with GameStop. But there's more to the story.

Related Videos

GameStop Mania: Which Meme Stocks Will Follow?
Profit Like Congress: The Stocks They’re Betting On
Home Depot: Earnings Mixed, Wait to Buy the Dip

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines